Becton Dickinson (1BDX) Stock Price & Analysis
1BDX Stock Chart & Stats
- Day’s Range
- EUR 177.45 - EUR 178.85
- 52-Week Range
- EUR 74.00 - EUR 265.00
- Previous Close
- EUR 175.85
- Volume
- N/A
- Average Volume (3M)
- 3
- Market Cap
- EUR 48.26B
- Enterprise Value
- EUR 57.58B
- Total Cash (Recent Filing)
- EUR 709.00M
- Total Debt (Recent Filing)
- EUR 16.81B
- Price to Earnings (P/E)
- 59.6
- Beta
- 0.43
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 3.64
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.93%
Bulls Say, Bears Say
Bulls Say
Recurring Healthcare Demand
BD’s large consumables base supports repeat purchasing because needles, catheters, specimen products, reagents, and related supplies are embedded in routine care. This recurring model can provide durable revenue visibility and customer stickiness across healthcare settings.
Broad Portfolio Growth
Growth across most of the portfolio reduces reliance on a single product or end market and indicates broad customer adoption. Double-digit expansion in selected platforms can strengthen BD’s mix, support reinvestment, and improve medium-term growth durability.
Improving Cash Generation
A substantial year-over-year improvement in free cash flow increases BD’s ability to fund innovation, reduce debt, and return capital without relying solely on external financing. Stronger cash generation also provides resilience while the company manages portfolio and operating investments.
Bears Say
Recent Earnings Deterioration
The recent contraction in revenue and net margin shows that BD’s otherwise stable operating model is not currently translating into consistent bottom-line growth. If the weaker demand, mix, or cost trends persist, they could constrain earnings quality and internal funding capacity.
Alaris Revenue Headwind
The defined Alaris remediation impact creates a visible drag on near-term organic growth and makes comparisons harder over the next several quarters. Even with normalization later, the headwind may limit reported momentum and require pricing or productivity gains to offset it.
Leverage Above Target
Leverage above management’s target reduces financial flexibility and leaves more cash flow allocated to balance-sheet repair rather than growth investment or shareholder returns. Although the debt level is described as manageable, deleveraging remains an important execution requirement.
Becton Dickinson News
1BDX FAQ
What was Becton Dickinson’s price range in the past 12 months?
What is Becton Dickinson’s market cap?
When is Becton Dickinson’s upcoming earnings report date?
How were Becton Dickinson’s earnings last quarter?
Is Becton Dickinson overvalued?
Does Becton Dickinson pay dividends?
What is Becton Dickinson’s EPS estimate?
How many shares outstanding does Becton Dickinson have?
What happened to Becton Dickinson’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Becton Dickinson?
What is the TipRanks Smart Score and how is it calculated?
Becton Dickinson Stock Smart Score
Company Description
Becton Dickinson
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Thomas E. Polen Jr.
- Employees
- 72,000
- Website
- www.bd.com
- Address
- 1 Becton Drive, Franklin Lakes, NJ, 07417-1880, US
Becton Dickinson (1BDX) Earnings & Revenues
1BDX Company Deck
1BDX Earnings Call
Earnings Call SentimentPositive
The call conveyed strong execution across BD's focused med‑tech portfolio: revenue and adjusted EPS beat expectations, growth platforms showed double-digit expansion, productivity and cash flow improved materially, and the company raised EPS guidance. Headwinds are defined and manageable — chiefly Alaris remediation, tariffs, vaccine weakness in China and some margin pressure versus the prior year — and management laid out clear mitigation actions (pricing, productivity, commercial investments, AI for supply chain). Overall the positives materially outweigh the negatives.
View all IT:1BDX earnings summaries1BDX Net sales Breakdown
- 52.45% Medical
- 23.66% Life Sciences
- 23.89% Interventional
1BDX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 4 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 12 | 0 | 0 |
